Inactivation of Rifampin by Nocardia Brasiliensis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1993 Jun 1

PMID 8328779

Citations 19

Authors

K Yazawa

Y Mikami

A Maeda

M Akao

N Morisaki

S Iwasaki

Affiliations

Soon will be listed here.

Abstract

Rifampin was glycosylated by a pathogenic species of Nocardia, i.e., Nocardia brasiliensis. The structures of two glycosylated compounds (RIP-1 and RIP-2) isolated from the culture broth of the bacterium were determined to be 3-formyl-23-(O-[beta-D-glucopyranosyl])rifamycin SV and 23-(O-[beta-D-glucopyranosyl])rifampin, respectively. Both compounds lacked antimicrobial activity against other gram-positive bacteria as well as the Nocardia species.

Citing Articles

Recent Advances in Antimicrobial Resistance: Insights from as a Model Organism.

Zhang Z, Wei M, Jia B, Yuan Y Microorganisms. 2025; 13(1).

PMID: 39858819 PMC: 11767524. DOI: 10.3390/microorganisms13010051.

Amino acid substitutions in the region between RpoB clusters II and III on rifampin susceptibility in Haemophilus influenzae.

Ho C, Chen C, Hsieh C, Su P Eur J Clin Microbiol Infect Dis. 2023; 42(12):1499-1509.

PMID: 37906391 DOI: 10.1007/s10096-023-04689-4.

C25-modified rifamycin derivatives with improved activity against .

Paulowski L, Beckham K, Johansen M, Berneking L, Van N, Degefu Y PNAS Nexus. 2023; 1(4):pgac130.

PMID: 36714853 PMC: 9802118. DOI: 10.1093/pnasnexus/pgac130.

The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification.

El-Khoury C, Mansour E, Yuliandra Y, Lai F, Hawkins B, Du J RSC Med Chem. 2022; 13(11):1276-1299.

PMID: 36439977 PMC: 9667779. DOI: 10.1039/d2md00263a.

Activation of the SigE-SigB signaling pathway by inhibition of the respiratory electron transport chain and its effect on rifampicin resistance in Mycobacterium smegmatis.

Oh Y, Lee H, Jeong J, Kim S, Oh J J Microbiol. 2022; 60(9):935-947.

PMID: 35913593 DOI: 10.1007/s12275-022-2202-0.

References

Maggi N, Pasqualucci C, BALLOTTA R, SENSI P . Rifampicin: a new orally active rifamycin. Chemotherapy. 1966; 11(5):285-92. DOI: 10.1159/000220462. View

Yazawa K, Mikami Y, Ohashi S, Miyaji M, Ichihara Y, Nishimura C . In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. J Antimicrob Chemother. 1992; 29(2):169-72. DOI: 10.1093/jac/29.2.169. View

Fuhrer H . [Coordination of the 13C-NMR. spectrum of rifamycin S on the basis of selective uncoupling of protons]. Helv Chim Acta. 1973; 56(7):2377-86. DOI: 10.1002/hlca.19730560721. View

Benveniste R, Davies J . Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc Natl Acad Sci U S A. 1973; 70(8):2276-80. PMC: 433717. DOI: 10.1073/pnas.70.8.2276. View

BRUFANI M, Cerrini S, FEDELI W, VACIAGO A . Rifamycins: an insight into biological activity based on structural investigations. J Mol Biol. 1974; 87(3):409-35. DOI: 10.1016/0022-2836(74)90094-1. View

Arora S, Main P . Correlation of structure and activity in ansamycins: molecular structure of cyclized rifamycin SV. J Antibiot (Tokyo). 1984; 37(2):178-81. DOI: 10.7164/antibiotics.37.178. View

Lisitsyn N, Sverdlov E, Moiseyeva E, Danilevskaya O, Nikiforov V . Mutation to rifampicin resistance at the beginning of the RNA polymerase beta subunit gene in Escherichia coli. Mol Gen Genet. 1984; 196(1):173-4. DOI: 10.1007/BF00334112. View

Mikami Y, Takahashi K, Yazawa K, Arai T, Namikoshi M, Iwasaki S . Biosynthetic studies on saframycin A, a quinone antitumor antibiotic produced by Streptomyces lavendulae. J Biol Chem. 1985; 260(1):344-8. View

Yamada T, Nagata A, Ono Y, Suzuki Y, Yamanouchi T . Alteration of ribosomes and RNA polymerase in drug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1985; 27(6):921-4. PMC: 180187. DOI: 10.1128/AAC.27.6.921. View

10.

Kuo M, Chirby D, ARGOUDELIS A, Cialdella J, Coats J, Marshall V . Microbial glycosylation of erythromycin A. Antimicrob Agents Chemother. 1989; 33(12):2089-91. PMC: 172826. DOI: 10.1128/AAC.33.12.2089. View

11.

Yazawa K, Mikami Y, Uno J . In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262). Antimicrob Agents Chemother. 1989; 33(12):2140-1. PMC: 172836. DOI: 10.1128/AAC.33.12.2140. View

12.

CAVALLERI B, Turconi M, Tamborini G, OCCELLI E, Cietto G, PALLANZA R . Synthesis and biological activity of some derivatives of rifamycin P. J Med Chem. 1990; 33(5):1470-6. DOI: 10.1021/jm00167a029. View

13.

Andersen S, Dabbs E . Cloning of nocardioform DNA conferring the ability to inactivate rifampicin. FEMS Microbiol Lett. 1991; 63(2-3):247-50. DOI: 10.1016/0378-1097(91)90093-p. View

14.

Yazawa K, Mikami Y, Maeda A, Kudo T, Suzuki K, Saito N . Inactivation of kanamycin A by phosphorylation in pathogenic Nocardia. Microbiol Immunol. 1991; 35(1):39-48. DOI: 10.1111/j.1348-0421.1991.tb01531.x. View

15.

Klemens S, Cynamon M . In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother. 1991; 35(10):2026-30. PMC: 245319. DOI: 10.1128/AAC.35.10.2026. View

16.

Arora S, Arjunan P . Molecular structure and conformation of rifamycin S, a potent inhibitor of DNA-dependent RNA polymerase. J Antibiot (Tokyo). 1992; 45(3):428-31. DOI: 10.7164/antibiotics.45.428. View

17.

Wehrli W, STAEHELIN M . Actions of the rifamycins. Bacteriol Rev. 1971; 35(3):290-309. PMC: 378391. DOI: 10.1128/br.35.3.290-309.1971. View